Dawn Health

Based in Copenhagen, Dawn Health A/S operates as a specialized digital health company, focusing on the development of regulated software for the global life science industry. The firm was established in 2016 through a joint effort by Daniel Gewecke Daugaard and Trifork, an IT services provider, with the objective of advancing digital solutions for healthcare.

The company's core business involves creating Software as a Medical Device (SaMD) and Digital Therapeutics (DTx) for large international pharmaceutical companies. This is delivered through a Software-as-a-Service (SaaS) model, where clients like Merck and Novartis utilize the Dawn Platform and Product Suite. These digital tools are designed to support patients with chronic conditions such as oncology, multiple sclerosis, and rare pediatric growth disorders. The platform enables patients to manage their treatment, track symptoms, and communicate with their healthcare providers, while offering pharmaceutical partners valuable real-world evidence and data analytics capabilities. Revenue is generated via this SaaS model, providing these regulated digital products to its pharma client base.

Dawn Health provides a product suite built on a modular platform, which allows for accelerated development and deployment of its solutions. Key offerings include a therapy companion app for patient support, disease management tools, and remote monitoring solutions that integrate with wearables. A significant feature is the platform's ability to collect patient-reported outcomes, generating real-world evidence to support regulatory filings and deepen the understanding of therapy impact. This capability is intended to shorten the development cycle for regulated digital health products from years to months.

The company has achieved significant financial milestones, securing total funding of $41.5 million over three rounds. A major Series A funding round in November and December 2021 brought in $25 million from a consortium including Chr. Augustinus Fabrikker and Vaekstfonden. This was followed by a Series B round in May 2025, raising €11.5 million from existing investors to further scale its platform and product suite.

Keywords: digital health, SaMD, Software as a Medical Device, Digital Therapeutics, DTx, life sciences, pharmaceutical industry, chronic disease management, real-world evidence, patient-reported outcomes, SaaS, healthtech, regulated software, therapy companion app, remote patient monitoring, Novartis, Merck, oncology, multiple sclerosis, Copenhagen